Benson MD, Buxbaum JN, Eisenberg DS et al (2020) Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 27:217–222. https://doi.org/10.1080/13506129.2020.1835263

Article  CAS  PubMed  Google Scholar 

Gilstrap LG, Dominici F, Wang Y et al (2019) Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail 12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407

Article  PubMed  PubMed Central  Google Scholar 

Kazi DS, Bellows BK, Baron SJ et al (2020) Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation 141:1214–1224. https://doi.org/10.1161/CIRCULATIONAHA.119.045093

Article  PubMed  PubMed Central  Google Scholar 

Ternacle J, Krapf L, Mohty D et al (2019) Aortic Stenosis and Cardiac Amyloidosis. JACC 74:2638–2651. https://doi.org/10.1016/j.jacc.2019.09.056

Article  PubMed  Google Scholar 

Tanskanen M, Peuralinna T, Polvikoski T, et al (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study

Cornwell GG, Murdoch WL, Kyle RA et al (1983) Frequency and distribution of senile cardiovascular amyloid: A clinicopathologic correlation. Am J Med 75:618–623. https://doi.org/10.1016/0002-9343(83)90443-6

Article  PubMed  Google Scholar 

Maurer MS, Hanna M, Grogan M et al (2016) Genotype and Phenotype of Transthyretin Cardiac Amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS). J Am Coll Cardiol 68:161–172. https://doi.org/10.1016/j.jacc.2016.03.596

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN (2015) Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 22:171–174. https://doi.org/10.3109/13506129.2015.1051219

Article  CAS  PubMed  Google Scholar 

Gorram F, Olsson M, Alarcon F et al (2021) New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis 28:84–90. https://doi.org/10.1080/13506129.2020.1841623

Article  CAS  Google Scholar 

Reilly MM, Staunton H, Harding AE (1995) Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 59:45–49. https://doi.org/10.1136/jnnp.59.1.45

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekijima Y, Nakamura K (1993) Hereditary Transthyretin Amyloidosis. In: Adam MP, Feldman J, Mirzaa GM, et al (eds) GeneReviews®. University of Washington, Seattle, Seattle (WA)

Buxbaum J, Alexander A, Koziol J et al (2010) Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 159:864–870. https://doi.org/10.1016/j.ahj.2010.02.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson D, Tagoe C, Schwartzbard A et al (2011) Relation of Clinical, Echocardiographic and Electrocardiographic Features of Cardiac Amyloidosis to the Presence of the Transthyretin V122I Allele in Older African-American Men. Am J Cardiol 108:440–444. https://doi.org/10.1016/j.amjcard.2011.03.069

Article  CAS  PubMed  Google Scholar 

Madhani A, Sabogal N, Massillon D et al (2023) Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc 12:e028973. https://doi.org/10.1161/JAHA.122.028973

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quarta CC, Buxbaum JN, Shah AM et al (2015) The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. N Engl J Med 372:21–29. https://doi.org/10.1056/NEJMoa1404852

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plante-Bordeneuve V (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40:120e–1120. https://doi.org/10.1136/jmg.40.11.e120

Article  Google Scholar 

Lane T, Fontana M, Martinez-Naharro A et al (2019) Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation 140:16–26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169

Article  CAS  PubMed  Google Scholar 

Fontana M, Berk JL, Gillmore JD, et al Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med 0: https://doi.org/10.1056/NEJMoa2409134

Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 133:2404–2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612

Article  CAS  PubMed  Google Scholar 

Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689

Article  CAS  PubMed  Google Scholar 

Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med 390:132–142. https://doi.org/10.1056/NEJMoa2305434

Article  CAS  PubMed  Google Scholar 

Maurer MS, Kale P, Fontana M et al (2023) Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med 389:1553–1565. https://doi.org/10.1056/NEJMoa2300757

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer MS, Elliott P, Comenzo R et al (2017) Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation 135:1357–1377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438

Article  PubMed  PubMed Central  Google Scholar 

Kittleson MM, Maurer MS, Ambardekar AV et al (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 142:e7–e22. https://doi.org/10.1161/CIR.0000000000000792

Article  PubMed  Google Scholar 

Vrana JA, Gamez JD, Madden BJ et al (2009) Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimens. Blood 114:4957–4959. https://doi.org/10.1182/blood-2009-07-230722

Article  CAS  PubMed  Google Scholar 

Castano A, Haq M, Narotsky DL et al (2016) Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol 1:880–889. https://doi.org/10.1001/jamacardio.2016.2839

Article  PubMed  Google Scholar 

Bokhari S, Castaño A, Pozniakoff T et al (2013) 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging 6:195–201. https://doi.org/10.1161/CIRCIMAGING.112.000132

Article  PubMed  PubMed Central  Google Scholar 

Schafer EB, Tushak Z, Trankle CR et al (2021) False-Positive 99mTechnetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy. Circ Heart Fail 14:e007558. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007558

Article  PubMed  Google Scholar 

Chang ICY, Bois JP, Bois MC et al (2018) Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium–Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Circ Cardiovasc Imaging 11:e007059. https://doi.org/10.1161/CIRCIMAGING.117.007059

Article  PubMed  Google Scholar 

Miller EJ, Campisi R, Shah NR et al (2022) Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. J Nucl Cardiol 29:2748–2760. https://doi.org/10.1007/s12350-022-03059-5

Article  PubMed  PubMed Central